Nanodropper announced that Bedo Solutions and Viseon Labs have agreed on terms to join its precision eyecare platform under a new corporate identity: Mu Medical. According to a company press release, this planned consolidation marks a major expansion for Nanodropper, evolving the company from a single-product device manufacturer into a broader commercial-stage medtech ecosystem. 

Following closing, the company's leadership structure will include: Allisa Song, MD, founder and CEO of Nanodropper, serving as CEO and board chair of Mu Medical; Sina Fateh, MD, founder and CEO of Viseon Labs, joining as chief strategy officer and board observer; Robert Kinast, MD, founder and CEO of Bedo Solutions, serving as board observer and medical advisor

Following completion of the transactions, Mu Medical will be organized around 4 complementary product verticals:

• Consumer Devices: Nanodropper Adaptor and GentleDrop are patient-centered eyedrop tools that optimize existing treatments and support daily therapy.
• Primary Packaging: MuPACK-JT2, MuVEYE, and MuMIST enable precision dosing at the source through proprietary micro-volume delivery technologies.
• Monitoring and Oculomics: VuTRACK leverages machine vision to enable adherence tracking and generate actionable health insights.
• AI Therapeutics: Myopia AI and VizGuard apply advanced analytics to support personalized treatment through AI-powered solutions.

The company says that together, these verticals form an integrated approach to modernizing eyecare: from how therapies are delivered and monitored to how treatment decisions are informed. OM